The new funding phase (2019-will employ nine people directly and includes 68 academic investigators across nine partner institutions. The new advanced research programme covers the full scope of pharmaceutical R&D with the exception of the discovery of new chemical entities under five research themes themes (PharM5), Molecules, Materials, Medicines, Manufacturing 和 Modelling with leading academic experts.
I类分子： New methodologies for the asymmetric synthesis of existing APIs & future drug c和idates. II类分子： Develop molecules & methods for automated & in flow generation of targeted drug hybrids. 三分子： Rapid initial toxicity & biological efficacy testing: new chemical entities, combinations 和 formulations.
材料： Advance our underst和ing of SCCMs & MCCMs in order to enable improved orally delivered drug products.
药物： Optimise the development, production & use of safe & effective medicines.
制造业： Enabling a disruptive change in the manufacture of drug substances 和 drug products.
造型： New techniques to design and predict behaviour in silico in order to reduce trial-和-error experimentation.
The SSPC community of 132 researchers is involved in 20 research projects. Recent collaborative projects include:
An SFI-funded SPOKES project MOMEnTUM (Modelling of Multi-Phase Transport Processes to Enable Automation in Manufacturing), a collaboration between SSPC and industry partners Johnson & Johnson Automation Centre of Excellence 和 AAL俄罗斯铝业公司
An SFI funded US-爱尔兰 R&D partnership 和 first of its kind “Centre to Centre” project to research continuous manufacturing for nano-based pharmaceutical drugs. (国际 collaboration)
Advanced biopharmaceutical technologies. SSPC works with seven industry partners 和 three research-performing organisations